How should methotrexate (MTX) be initiated in a patient with rheumatoid arthritis?

How to Start Methotrexate for Rheumatoid Arthritis

Start methotrexate at 15 mg weekly (or at least 10 mg weekly), escalate to 15-25 mg within 4-6 weeks, use oral administration initially, and provide folic acid supplementation. 1

Initial Dosing Strategy

The starting dose should be at least 15 mg weekly, with escalation to approximately 0.3 mg/kg (typically 20-25 mg/week in Western populations) within 4-6 weeks. 1 The 2021 ACR guidelines specifically recommend initiation/titration to at least 15 mg weekly within this timeframe, though this is a conditional recommendation due to variation in physician and patient preferences regarding the tradeoff between efficacy and toxicity 1. The EULAR guidelines emphasize that this rapid escalation is critical, as methotrexate is the anchor drug for RA treatment 1.

Dosing Considerations:

• Starting doses below 10 mg weekly are inadequate 2
• Target dose is 20-25 mg/week in most Western patients (approximately 0.3 mg/kg) 1
• Asian populations may require lower maximum doses (e.g., 16 mg in Japan) due to lower body weight and possible pharmacogenetic differences 1
• Dose escalation should occur in 2.5-5 mg increments every 2 weeks until reaching the target dose or achieving disease control 3, 2

Route of Administration

Begin with oral methotrexate for ease of administration and patient acceptance. 1 The ACR conditionally recommends oral over subcutaneous administration when initiating therapy, despite moderate evidence suggesting superior efficacy of subcutaneous injections, because of similar bioavailability at typical starting doses and ease of oral administration 1.

When to Switch to Subcutaneous/Intramuscular:

• Poor response to oral methotrexate at adequate doses 1, 3
• Gastrointestinal side effects (nausea, vomiting, diarrhea) 1, 3, 2
• Poor compliance or polypharmacy concerns 3, 2
• Doses exceeding 20 mg/week (better absorption with parenteral route) 3
• Obesity (if doses >20 mg/week are required) 3

Research demonstrates that subcutaneous methotrexate achieves 85% ACR20 response compared to 77% with oral administration 4, making route optimization a critical step before declaring treatment failure.

Mandatory Pre-Treatment Assessment

Before initiating methotrexate, obtain the following 5, 2:

Required Laboratory Tests:

• Complete blood count (CBC) 5, 2
• Serum creatinine with calculated creatinine clearance (must be >60 mL/min) 5, 2
• Liver transaminases (AST/ALT) 5, 2
• Chest radiograph 2

Recommended Additional Tests:

• Hepatitis B and C serologies 2
• Serum albumin 2
• Pulmonary function tests with DLCO if respiratory history or symptoms present 2

Folic Acid Supplementation

Provide folic acid supplementation routinely to all patients starting methotrexate. 1, 2 A minimum dose of 5 mg folic acid once weekly, taken at a different time than the methotrexate dose, is appropriate 2. The EULAR guidelines emphasize that folic acid supplementation is a central aspect of methotrexate therapy 1.

Monitoring Schedule

Monitor CBC, liver transaminases, and serum creatinine at least monthly for the first 3 months, then every 4-12 weeks thereafter. 5, 2 More frequent monitoring (every 1-1.5 months) should continue until the patient achieves stability, then can be extended to every 1-3 months 3.

Key Monitoring Parameters:

• Maximal myelosuppression typically occurs 7-10 days after dosing 5
• Hold methotrexate if serum creatinine increases by ≥50% from baseline 5
• Hold if transaminases exceed 2× upper limit of normal 5
• Hold if mucositis or persistent pleural effusion develops 5

Managing Inadequate Response

If disease activity remains moderate-to-high after reaching 15-20 mg weekly:

1. First, switch to subcutaneous administration before adding or switching to other DMARDs 1
2. Consider split dosing (dividing the weekly dose over 24 hours) 1
3. Increase folic/folinic acid supplementation 1
4. Escalate dose up to 25 mg weekly (or even 30 mg in select cases, though toxicity risk increases significantly above 20 mg/week) 1, 5

The ACR specifically recommends maximizing methotrexate optimization before concluding treatment failure 1.

Common Pitfalls to Avoid

• Starting at doses <10 mg weekly: This is inadequate and delays therapeutic response 1, 2
• Slow dose escalation: Waiting longer than 4-6 weeks to reach therapeutic doses reduces efficacy 1
• Omitting folic acid: Increases toxicity without improving efficacy 1, 2
• Switching DMARDs before optimizing methotrexate route and dose: Subcutaneous administration and dose optimization should be attempted first 1, 4
• Inadequate patient education: Patients often fear methotrexate due to its use in cancer at high doses; education about low-dose safety is essential 1

Expected Timeline for Response

Therapeutic response typically begins within 3-6 weeks, with continued improvement for up to 12 weeks or more. 5 If arthritis worsens within 3-6 weeks after discontinuation, this confirms methotrexate efficacy 5.